Shasun Chemicals technology licenses API technology to Merck

Shasun Chemicals & Drugs Ltd today said that it had entered into a non-exclusive licensing agreement with Merck & Co., Inc. to allow the US drug firm the use of its proprietary cross-coupling copper technology (also known as Buchwald technology) to manufacture and commercialize active pharmaceutical ingredients (APIs).

The Buchwald cross-coupling technology is one of the most popular technologies in the pharmaceutical area allowing increasingly complex new drugs to be manufactured in an efficient and economical way.

Commenting on this development, Dr. Michel Spagnol, chief technology officer, said, " This is an important milestone for Shasun in making this technology widely accessible and paving the way for further collaborations."